FY28 SBIR Contract Topic: Adjuvant Down-Selection and Development for Vaccines for Infectious, Allergic, and Immune-Mediated Diseases
Forecast New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $7,000,000 to $13,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new FY28 SBIR contract topic, "Adjuvant Down-Selection and Development for Vaccines for Infectious, Allergic, and Immune-Mediated Diseases," with an estimated solicitation release date of January 1, 2028 and an estimated award date of June 1, 2028. The topic seeks SBIR R&D proposals on adjuvant development, including down-selection of adjuvants from previously performed high-throughput screens, to produce novel vaccine adjuvants for use in safe and effective vaccines. The forecast is set aside for Total Small Business and is classified under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The estimated award value range is $7.0 million to $13.0 million. The National Institute of Allergy and Infectious Diseases (NIAID) requested inclusion of this topic and states that, without approval, it cannot solicit novel adjuvant development from small businesses. Points of contact are Callie Prassinos, Contracting Officer at NIH (callie.prassinos@nih.gov, +1 240-669-5155), and Aaron Joffe, National Institutes of Health (ari.joffe@nih.gov).
Forecast text
This request is for inclusion of a FY28 SBIR Contract topic entitled: "Adjuvant Down-Selection and Development for Vaccines for Infectious, Allergic, and Immune-Mediated Diseases". This contract topic will solicit SBIR R&D proposals on subjects relevant to adjuvant development, including down-selection of adjuvants from previously performed high-throughput screens. The purpose of this proposal is to enable development of novel vaccine adjuvants that can be used in safe and effective vaccines in the future. If this request is not approved, NIAID will not be able to solicit the development of novel adjuvants from small buisinesses, which will ultimately limit progress on improved vaccines and the NIH's ability to support small buisinesses via the SBIR program.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast